Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
Cibil Report
Get cibil report
My Account
Log In
Log into your account
Offers
Check out pre-approved offers now!
Languages
Chosen Language: English
Do Not Call
Do not call
En
Curis Lifesciences Ltd. Share Price
N/A
1D
1M
3M
6M
1Y
5Y
Day's Range
Day's Range
Low
₹0.00
High
₹0.00
Price Summary
| Previous Close | ₹118.10 |
|---|---|
| Day's Range | ₹0.00 - ₹0.00 |
| Open | ₹0.00 |
| 52 Week Range | ₹83.60 - ₹147.90 |
| Volume | 0 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 16.02 |
| TTM EPS (₹) | 7.55 |
| P/E Ratio | 0.00 |
| Book Value(₹) | 5.32 |
| PAT Margin (%) | 12.43 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 34.25 |
About Curis Lifesciences Ltd.
| Founded | 2016 |
|---|---|
| Managing Director | Dharmesh Dasharathbhai Patel |
| NSE Symbol | CURIS |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,36,858.91 | 1,826.30 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,76,617.57 | 6,636.50 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,44,717.58 | 4,314.75 | 3,101.60 - 3,101.60 |
| Apollo Hospitals Enterprise Ltd. | 1,11,737.93 | 7,766.00 | 6,677.50 - 6,677.50 |
| Cipla Ltd. | 1,07,721.85 | 1,337.40 | 1,165.70 - 1,165.70 |
| Lupin Ltd. | 1,07,143.97 | 2,382.85 | 1,836.80 - 1,836.80 |
| Dr. Reddy's Laboratories Ltd. | 1,06,080.73 | 1,279.65 | 1,129.40 - 1,129.40 |
| Max Healthcare Institute Ltd. | 97,300.05 | 1,008.80 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 95,803.01 | 2,311.40 | 1,909.70 - 1,909.70 |
| Zydus Lifesciences Ltd. | 91,753.45 | 923.00 | 835.50 - 835.50 |
No Records Found
Latest News
May
6
2026
Posted on May 6th 2026
Aurobindo Pharma informs about updates
Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that the United States Food and Drug Administration (US FDA) inspected Aurobindo Pharma’s Unit-VII, an oral solid dosage manufacturing unit, situated at Special Economic Zone (Pharma), TSIIC, Green Industrial Park, Polepally Village, Jedcherla Mandal, Mahaboobnagar District, 509302, Telangana from January 28 to February 10, 2026. At the end of the inspection, a ‘Form 483’ was issued with a total of 9 observations. The Unit has now received Establishment Inspection Report (EIR) classifying the facility as ‘Voluntary Action Indicated’ (‘VAI’). FDA has concluded that this inspection is now closed.
The above information is a part of company’s filings submitted to BSE.
Read More
May
6
2026
Posted on May 6th 2026
Ajanta Pharma - Quaterly Results
The Revenue for the quarter ended March 2026 of Rs. 12105.30 millions grew by 19.39 % from Rs. 10139.40 millions.Net profit showed a marginal rise at Rs. 1972.80 millions for the quarter ended March 2026, as compared to corresponding quarter of last year.Operating profit surged to 3010.30 millions from the corresponding previous quarter of 2675.80 millions.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 12105.30 | 10139.40 | 19.39 | 48459.20 | 43220.40 | 12.12 | 48459.20 | 43220.40 | 12.12 |
| Other Income | 629.80 | 179.30 | 251.25 | 2044.00 | 1198.70 | 70.52 | 2044.00 | 1198.70 | 70.52 |
| PBIDT | 3010.30 | 2675.80 | 12.50 | 14023.90 | 13245.90 | 5.87 | 14023.90 | 13245.90 | 5.87 |
| Interest | -7.40 | 6.70 | -210.45 | 25.90 | 46.00 | -43.70 | 25.90 | 46.00 | -43.70 |
| PBDT | 3017.70 | 2669.10 | 13.06 | 13998.00 | 13199.90 | 6.05 | 13998.00 | 13199.90 | 6.05 |
| Depreciation | 441.60 | 387.60 | 13.93 | 1687.70 | 1399.30 | 20.61 | 1687.70 | 1399.30 | 20.61 |
| PBT | 2576.10 | 2281.50 | 12.91 | 12310.30 | 11800.60 | 4.32 | 12310.30 | 11800.60 | 4.32 |
| TAX | 603.30 | 347.20 | 73.76 | 2842.10 | 2631.70 | 7.99 | 2842.10 | 2631.70 | 7.99 |
| Deferred Tax | -70.00 | -43.80 | 59.82 | 76.00 | 51.40 | 47.86 | 76.00 | 51.40 | 47.86 |
| PAT | 1972.80 | 1934.30 | 1.99 | 9468.20 | 9168.90 | 3.26 | 9468.20 | 9168.90 | 3.26 |
| Equity | 250.70 | 250.70 | 0.00 | 250.70 | 250.70 | 0.00 | 250.70 | 250.70 | 0.00 |
| PBIDTM(%) | 24.87 | 26.39 | -5.77 | 28.94 | 30.65 | -5.57 | 28.94 | 30.65 | -5.57 |
Read More
May
6
2026
Posted on May 6th 2026
Emcure Pharma - Quaterly Results
A fair growth of 14.83% in the revenue at Rs. 14677.03 millions was reported in the March 2026 quarter as compared to Rs. 12781.88 millions during year-ago period.Net profit surges 67.46% to Rs. 2336.97 millions from Rs. 1395.57 millions in the quarter ended March 2026.The company reported a good operating profit of 3985.94 millions compared to 2670.33 millions of corresponding previous quarter.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 14677.03 | 12781.88 | 14.83 | 52431.88 | 43819.24 | 19.65 | 52431.88 | 43819.24 | 19.65 |
| Other Income | 269.39 | 223.96 | 20.28 | 2095.16 | 1188.07 | 76.35 | 2095.16 | 1188.07 | 76.35 |
| PBIDT | 3985.94 | 2670.33 | 49.27 | 13342.66 | 7656.44 | 74.27 | 13342.66 | 7656.44 | 74.27 |
| Interest | 368.67 | 240.69 | 53.17 | 1182.71 | 1129.62 | 4.70 | 1182.71 | 1129.62 | 4.70 |
| PBDT | 3693.06 | 2429.64 | 52.00 | 11909.24 | 6526.82 | 82.47 | 11909.24 | 6526.82 | 82.47 |
| Depreciation | 630.40 | 569.12 | 10.77 | 2467.33 | 2249.72 | 9.67 | 2467.33 | 2249.72 | 9.67 |
| PBT | 3062.66 | 1860.52 | 64.61 | 9441.91 | 4277.10 | 120.75 | 9441.91 | 4277.10 | 120.75 |
| TAX | 725.69 | 464.95 | 56.08 | 2112.32 | 1105.82 | 91.02 | 2112.32 | 1105.82 | 91.02 |
| Deferred Tax | -62.93 | -170.95 | -63.19 | -225.09 | -21.25 | 959.25 | -225.09 | -21.25 | 959.25 |
| PAT | 2336.97 | 1395.57 | 67.46 | 7329.59 | 3171.28 | 131.12 | 7329.59 | 3171.28 | 131.12 |
| Equity | 1895.90 | 1894.83 | 0.06 | 1895.90 | 1894.83 | 0.06 | 1895.90 | 1894.83 | 0.06 |
| PBIDTM(%) | 27.16 | 20.89 | 29.99 | 25.45 | 17.47 | 45.64 | 25.45 | 17.47 | 45.64 |
Read More
May
6
2026
Posted on May 6th 2026
Sandu Pharmaceutical - Quaterly Results
The Revenue for the quarter ended March 2026 of Rs. 168.53 millions grew by 19.79 % from Rs. 140.69 millions.The company reported a drastic decline of -86.85% in the quarter ended March 2026 to Rs. 0.43 millions from Rs. 3.27 millions .OP of the company witnessed a marginal growth to 9.38 millions from 5.17 millions in the same quarter last year.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 168.53 | 140.69 | 19.79 | 699.34 | 671.92 | 4.08 | 699.34 | 671.92 | 4.08 |
| Other Income | 3.65 | 0.69 | 428.99 | 4.44 | 1.68 | 164.29 | 4.44 | 1.68 | 164.29 |
| PBIDT | 9.38 | 5.17 | 81.43 | 34.43 | 29.30 | 17.51 | 34.43 | 29.30 | 17.51 |
| Interest | 0.26 | 0.26 | 0.00 | 1.12 | 1.03 | 8.74 | 1.12 | 1.03 | 8.74 |
| PBDT | 9.12 | 4.91 | 85.74 | 33.31 | 28.27 | 17.83 | 33.31 | 28.27 | 17.83 |
| Depreciation | 1.65 | 1.48 | 11.49 | 6.77 | 6.71 | 0.89 | 6.77 | 6.71 | 0.89 |
| PBT | 7.47 | 3.43 | 117.78 | 26.54 | 21.56 | 23.10 | 26.54 | 21.56 | 23.10 |
| TAX | 7.04 | 0.16 | 4300.00 | 8.89 | 6.07 | 46.46 | 8.89 | 6.07 | 46.46 |
| Deferred Tax | 1.64 | -0.58 | -382.76 | 1.04 | 0.18 | 477.78 | 1.04 | 0.18 | 477.78 |
| PAT | 0.43 | 3.27 | -86.85 | 17.65 | 15.49 | 13.94 | 17.65 | 15.49 | 13.94 |
| Equity | 96.61 | 96.61 | 0.00 | 96.61 | 96.61 | 0.00 | 96.61 | 96.61 | 0.00 |
| PBIDTM(%) | 5.57 | 3.67 | 51.46 | 4.92 | 4.36 | 12.90 | 4.92 | 4.36 | 12.90 |
Read More
May
5
2026
Posted on May 5th 2026
Emmessar Biotech & Nutrition informs about board meeting
Emmessar Biotech & Nutrition has informed that a meeting of the Board of Directors of the Company will be held on Tuesday the May 12, 2026, at Mumbai, To consider and approve Audited Financial Results of the Company for the year ended 31st March, 2026. Further, pursuant SEBI (Prohibition of Insider Trading), Regulations, 2015, as amended from time to time the Trading Window, as informed to the exchange vide letter dated 30.03.2026 in respect of trading in equity shares of the Company will remain closed up to May 14, 2026.
The above information is a part of company’s filings submitted to BSE.
Read More
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Curis Lifesciences Ltd. is ₹118.10 as of 2026-05-06.
The market capitalisation of Curis Lifesciences Ltd. is ₹97.82 as of 2026-05-05.
The 1-year return of Curis Lifesciences Ltd. is -2.90% as of 2026-05-06.
The P/E ratio of Curis Lifesciences Ltd. is 0.00 as of 2026-05-06.
The 52-week high and low of Curis Lifesciences Ltd. are ₹147.90 and ₹83.60, respectively, as of 2026-05-06.
View More
Disclaimer
This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
Home
Shopping
Personal Loan
My Accounts
Explore